Gastrointestinal Cancer News

The FDA granted fast track designation to abelacimab for treatment of cancer-associated thrombosis, according to a press release from the agent’s manufacturer.

The development of targeted cancer therapies has led to improved clinical outcomes for many patients. However, monotherapies against a single target can result in treatment resistance.

Cold forceps polypectomies were effectively noninferior to cold snare polypectomies for complete resection of nonpedunculated polyps <3 mm, and required less time to perform, noted data published in The American Journal of Gastroenterology.

Widespread reductions in cancer screenings during the COVID-19 pandemic may be associated with delayed cancer diagnoses and increased mortality for breast, cervical and colon cancers, according to study results published in JAMA Oncology.

In this video, Michael Cecchini, MD, discussed a late-breaking abstract evaluating FOLFOXIRI plus panitumumab vs. mFOLFOX6 plus panitumumab as initial treatment of unresectable RAS and BRAF wild-type metastatic colorectal cancer.

In this video, Howard S. Hochester, MD, discusses the COMMIT study comparing the anti-PD1 drug atezolizumab with atezolizumab combined with FOLFOX chemotherapy presented as part of a poster session at ASCO Annual Meeting.

When Aparna Surapaneni, MD, began working in Memorial Hermann Health System’s radiation oncology department 6 years ago, she noticed a pull-up bar right outside her office.

The FDA granted orphan drug designation to several therapies in development for oncology indications.

The addition of tislelizumab to first-line chemotherapy extended OS among patients with advanced esophageal cancer, according to study results presented at European Society for Medical Oncology World Congress on Gastrointestinal Cancer.

Colorectal cancer screening prevalence remained low in 2018 among U.S. adults aged 50 to 54 years vs. 70 to 75 years, with the younger group exhibiting larger disparities by race/ethnicity, education level, income and insurance.